Abbott Laboratories (ABT) rose 1.21% to $103.18, ending six consecutive days of losses after agreeing to pay the DOJ $385 million to resolve claims related to its 2022 baby formula recall. The company admitted no wrongdoing. Despite a 21% year-over-year decline and a Seeking Alpha 'Hold' rating due to valuation concerns, Wall Street maintains a consensus 'Buy' rating, citing renewed momentum in nutrition, diagnostics, and medical devices.
